Cargando…

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc

Resistance to epidermal growth factor receptor (EGFR) targeted monoclonal antibody therapy represents a clinical challenge in patients suffered from RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, the molecular mechanisms and key factors conferring this resistance are largely unknow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yiyi, Guo, Mengzhou, Wei, Ye, Yu, Shan, Li, Hong, Wang, Yan, Xu, Xiaojing, Cui, Yuehong, Tian, Jiawen, Liang, Li, Peng, Ke, Liu, Tianshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348362/ https://www.ncbi.nlm.nih.gov/pubmed/27825133 http://dx.doi.org/10.18632/oncotarget.13105

Ejemplares similares

Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer
por: Xu, Xiaojing, et al.
Publicado: (2023)

FoxO3 suppresses Myc-driven lymphomagenesis
por: Vandenberg, C J, et al.
Publicado: (2016)

Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation
por: Liu, Ruiqi, et al.
Publicado: (2018)

Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer
por: Liang, Li, et al.
Publicado: (2021)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Association Study to Evaluate FoxO1 and FoxO3 Gene in CHD in Han Chinese
por: Zhao, Ying, et al.
Publicado: (2014)

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Zheng, Bobo, et al.
Publicado: (2019)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
por: Toledo, Rodrigo A., et al.
Publicado: (2016)

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Han, Yu Na, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
por: Han, Jiaqi, et al.
Publicado: (2020)

FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L
por: Yu, Shan, et al.
Publicado: (2016)

Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
por: Dai, Peilin, et al.
Publicado: (2022)

Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter
por: Tian, Yu-Nan, et al.
Publicado: (2020)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
por: Liu, Shousheng, et al.
Publicado: (2020)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability
por: Riddell, Meghan, et al.
Publicado: (2018)

FoxO Proteins in the Nervous System
por: Maiese, Kenneth
Publicado: (2015)

The FoxOs are in the ApoM house
por: Linton, MacRae F., et al.
Publicado: (2022)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Time-dependent modulation of FoxO activity by HDAC inhibitor in oncogene-transformed E1A+Ras cells
por: Morshneva, Alisa, et al.
Publicado: (2018)

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
por: Wang, Lu, et al.
Publicado: (2020)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
por: Bruera, Gemma, et al.
Publicado: (2019)

RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
por: Wu, Bin, et al.
Publicado: (2017)

Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study
por: Chang, Yu-Tang, et al.
Publicado: (2023)

FoxO gene family evolution in vertebrates
por: Wang, Minghui, et al.
Publicado: (2009)

Redox regulation of FoxO transcription factors
por: Klotz, Lars-Oliver, et al.
Publicado: (2015)

FoxO1 breaks diabetic heart
por: Nagao, Mototsugu, et al.
Publicado: (2013)

FoxO transcription factors in mitochondrial homeostasis
por: Cheng, Zhiyong
Publicado: (2022)

Correction: Time-dependent modulation of FoxO activity by HDAC inhibitor in oncogene-transformed E1A+Ras cells
por: Morshneva, Alisa, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r1kktulfs1viu73199lundjghf